- Home
- PTIX vs QLGN Comparison
PTIX vs QLGN Comparison
Compare PTIX & QLGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PTIX
- QLGN
- Stock Information
- Founded
- PTIX 1994
- QLGN 1996
- Country
- PTIX United States
- QLGN United States
- Employees
- PTIX N/A
- QLGN N/A
- Industry
- PTIX Biotechnology: Pharmaceutical Preparations
- QLGN Biotechnology: Pharmaceutical Preparations
- Sector
- PTIX Health Care
- QLGN Health Care
- Exchange
- PTIX Nasdaq
- QLGN Nasdaq
- Market Cap
- PTIX 2.8M
- QLGN 3.1M
- IPO Year
- PTIX 2016
- QLGN N/A
- Fundamental
- Price
- PTIX $2.78
- QLGN $1.90
- Analyst Decision
- PTIX
- QLGN
- Analyst Count
- PTIX 0
- QLGN 0
- Target Price
- PTIX N/A
- QLGN N/A
- AVG Volume (30 Days)
- PTIX 104.7K
- QLGN 116.2K
- Earning Date
- PTIX 08-22-2025
- QLGN 08-26-2025
- Dividend Yield
- PTIX N/A
- QLGN N/A
- EPS Growth
- PTIX N/A
- QLGN N/A
- EPS
- PTIX N/A
- QLGN N/A
- Revenue
- PTIX N/A
- QLGN N/A
- Revenue This Year
- PTIX N/A
- QLGN N/A
- Revenue Next Year
- PTIX N/A
- QLGN N/A
- P/E Ratio
- PTIX N/A
- QLGN N/A
- Revenue Growth
- PTIX N/A
- QLGN N/A
- 52 Week Low
- PTIX $2.35
- QLGN $1.61
- 52 Week High
- PTIX $15.54
- QLGN $11.50
- Technical
- Relative Strength Index (RSI)
- PTIX 41.42
- QLGN 32.76
- Support Level
- PTIX $2.60
- QLGN $1.61
- Resistance Level
- PTIX $3.24
- QLGN $1.91
- Average True Range (ATR)
- PTIX 0.27
- QLGN 0.16
- MACD
- PTIX 0.02
- QLGN 0.02
- Stochastic Oscillator
- PTIX 27.69
- QLGN 29.74
About PTIX Protagenic Therapeutics Inc.
Protagenic Therapeutics Inc is a biopharmaceutical company focused on the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. It provides treatments for mood, anxiety, depression, and neurodegenerative disorders by using peptide-based and brain-active therapeutics. The company's main compound, PT00114, is a synthetic form of Teneurin Carboxy-terminal Associated Peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. It has also created a portfolio of novel neuropeptides that are in various stages of development and preclinical evaluation for the treatment of mood disorders.
About QLGN Qualigen Therapeutics Inc.
Qualigen Therapeutics Inc is an early-clinical-stage therapeutics company focused on developing treatments for adult and pediatric cancer. The company's business consists of one early-clinical-stage therapeutic program (QN-302) and one preclinical therapeutic program. The company's program, QN-302, is an investigational small-molecule G-quadruplexes (G4)-selective transcription inhibitor with binding affinity to G4s prevalent in cancer cells.